A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: SIBP-01;   Drug: Herceptin;   Drug: Docetaxel;   Drug: Carboplatin Sponsors:   Shanghai Institute Of Biological Products;   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials